Back
New search
Date

MOPEAD, the early Alzheimer’s- Disease detection project, is presented at the 28th Alzheimer Europe Conference

29/10/2018



MOPEAD’s main remits are to favor early diagnosis, identify a patient-recruitment model and enhance AD therapies

As the project reaches its equator more than 1300 people have now taken part in the research, conducted on the citizen science model

The conference, held this year in Barcelona, is Europe’s number-one Alzheimer’s and dementia conference

GMV and Fundació ACE (Barcelona Alzheimer Treatment & Research Center) have presented the clinical-scientific research project MOPEAD (Models of Patient Engagement for Alzheimer’s Disease) and the results of its first two years of work at the 28th Alzheimer Europe Conference held this year in Barcelona.

Led by Fundació ACE, the main purpose of MOPEAD is to consolidate an early AD diagnosis system on the strength of active citizen participation while also raising public awareness of the importance of this research, in order to bring new cases to light. The study also aims to turn the vast amount of data handled into valuable evidence, helping doctors to take the right decisions and the pharmaceutical industry to develop new AD-restraining drugs as well as selecting the ideal people to take part in the clinical trials.

The 4-million-euro MOPEAD project is backed by the Innovative Medicines Initiative (IMI), a public-private consortium run as a partnership by the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

The neurologist Mercè Boada, medical director of Fundació ACE, is leading this research under the “citizen science” concept, whereby citizens contribute actively to science by their own intellectual effort and add to the stock of reliable scientific knowledge. In the case of Alzheimer’s Disease (AD) this citizen participation is particularly crucial to drive ongoing research, because, as Dr. Boada quite rightly points out, “once the diagnosis has become one of dementia, it means we’ve arrived on the scene too late. We need to arrive earlier to diagnose pre-dementia impairment and, in general, we’re unable to do this because society is unaware of the impairment symptoms. Because these symptoms don’t hurt we write them off as simply part of the ageing process. Recognizing these symptoms in time, however, by carrying out memory checkups, is crucial to achieve this earlier diagnosis”.

Milestones presented at Alzheimer Europe

The project has now been underway for two years, during which time free memory checks have been conducted at the various specialist clinics: Stockholm’s Karolinska Institutet Alzheimer’s research center; Ljubljana University Medical Center; Cologne University Hospital “Uniklinik Köln”; and Fundació ACE.

As Dr. Boada informed the conference, “the number of people taking part in this research has now topped 1300 and, of those that have been diagnosed with cognitive impairment, over 140 have gone on to the final phase of the study in the memory clinic”. The research project intends in the end to work with at least 2000 people aged 65 to 85, including citizens from Germany, Sweden, Slovenia, Spain and the Netherlands.

During this time the necessary technology has also been rolled out for all the following: online giving of disease information and cognitive testing; collecting clinical and demographic data furnished by specialists and managing test results; and extracting evidence from the information obtained by means of Big Data techniques.

In the words of Adrián Rodrigo, GMV’s smart health solutions specialist, “in the two short months in which the recruitment portal https://www.mopeadstudy.eu/ has been up and running it has chalked up over 13,000 hits. In September about 25% of the people visiting the portal came from Facebook campaigns; indeed, many of the people carrying out the test have done so urged on by their children”. The commonest Google search terms that have led respondents to the MOPEAD web portal, as pointed out by GMV’s specialist, included “Memory loss, AD symptoms, cognitive impairment, AD causes, first Alzheimer’s symptoms or is Alzheimer’s hereditary?”

These first results were unveiled in the special MOPEAD Symposium including within the agenda of the Alzheimer Europe Conference; this symposium was chaired by Dr. Boada and involved representatives from the various MOPEAD work groups, like Octavio Rodríguez (Fundació ACE), Andreea Ciudin (Hospital Vall d’Hebron), Anders Wimo (Karolinska Institutet), Annette Dumas (ASDM Consulting) and Adrián Rodrigo (GMV).

The MOPEAD project, led by Fundació ACE, also involves the participation of top-level organizations like Eli Lilly and Company Ltd.; ASDM Consulting; AstraZeneca AB; the European Institute of Women’s Health; GMV Soluciones Globales Internet SAU; Karolinska Institute; KITE Innovation (Europe) Ltd.; Spomincica-Alzheimer Slovenia; Cologne University Hospital; Ljubljana University Medical Center; Vall D’Hebron-Institut University Hospital Recerca; Stichting VUmc, Alzheimer Europe and GMV.

Alzheimer Europe Conference

The Europe Alzheimer Conference is Europe’s top Alzheimer’s and dementia conference. Every year it brings together a great number of dementia sufferers, carers and volunteers, together with the leading researchers, politicians, healthcare professionals and staff of Alzheimer associations.

The Europe Alzheimer Conference is convened yearly by Alzheimer Europe. This year’s 28th conference is being held from 29 to 31 October in Barcelona in collaboration with the Spanish Alzheimer’s Confederation (Confederación Española de Alzheimer: CEAFA) and the Spanish Alzheimer’s Foundation (Fundación Alzheimer España: FAE).